Company
Xaira Therapeutics
Xaira Therapeutics is a biotechnology company based in South San Francisco that uses artificial intelligence to accelerate drug discovery and development. The company integrates machine learning research, large-scale biological data generation, and therapeutic product development to advance drug discovery. Founded in 2023, Xaira develops foundational technologies including X-Cell and X-Atlas/Pisces platforms designed to improve how diseases are understood and treated.
Xaira Therapeutics is a privately held company operating in the biotech & pharma sector, based in USA. Leadership tracked by CEOInsider includes Marc Tessier-Lavigne (CEO).
Leadership
Current
Recent developments
AI summary of recent coverageRecent coverage has focused on Xaira Therapeutics' emergence as an AI-driven drug discovery company backed by a nearly $1 billion fundraise, with particular attention to the company's development of virtual cell models and computational platforms designed to accelerate early-stage research. Headlines have highlighted Xaira's launch of X-Cell, its first virtual cell model trained on large-scale genomic datasets, as well as the company's recent disclosure of an antibody platform and initial pipeline programs. Coverage has also noted leadership appointments and expansions at Xaira as the company scales operations to advance its AI-enabled approach to drug development.
Summarized from the headlines in the sidebar; see each source for the full story.